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Abstract
Statins, HMG-CoA reductase inhibitors, are used in the prevention and treatment of cardiovascular diseases owing
to their lipid-lowering effects. Previous studies revealed that, by modulating membrane cholesterol content, statins
could induce conformational changes in cluster of differentiation 20 (CD20) tetraspanin. The aim of the presented
study was to investigate the influence of statins on glucose transporter 1 (GLUT1)–mediated glucose uptake in
tumor cells. We observed a significant concentration- and time-dependent decrease in glucose analogs’ uptake
in several tumor cell lines incubated with statins. This effect was reversible with restitution of cholesterol synthesis
pathway with mevalonic acid as well as with supplementation of plasma membrane with exogenous cholesterol.
Abbreviations: 2-DOG, 2-deoxyglucose; 6-NBDG, 6-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-deoxyglucose; CD, cluster of differentiation; CRAC, cholesterol recognition/
interaction amino acid consensus; 18F-FDG, [18F]fluoro-2-deoxyglucose; FPP, farnesyl pyrophosphate; GLUT, glucose transporter; HA, hemagglutinin; MA, mevalonic acid; MβCD,
methyl-β-cyclodextrin; PBMC, peripheral blood mononuclear cell; PET/CT, positron emission tomography/computed tomography; SUV, standardized uptake value
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Statins did not change overall GLUT1 expression at neither transcriptional nor protein levels. An exploratory clinical
trial revealed that statin treatment decreased glucose uptake in peripheral blood leukocytes and lowered
18F-fluorodeoxyglucose (18F-FDG) uptake by tumor masses in a mantle cell lymphoma patient. A bioinformatics
analysis was used to predict the structure of human GLUT1 and to identify putative cholesterol-binding motifs in
its juxtamembrane fragment. Altogether, the influence of statins on glucose uptake seems to be of clinical signifi-
cance. By inhibiting 18F-FDG uptake, statins can negatively affect the sensitivity of positron emission tomography,
a diagnostic procedure frequently used in oncology.
Neoplasia (2012) 14, 311–323
Introduction
Owing to the deregulated blood supply, rapidly growing tumor cells
suffer from lack of oxygen and nutrients. An increased glucose metab-
olism seems to be an important mechanism of tumor cells adapting
to hypoxia. Intriguingly, transformed cells tend to use anaerobic gly-
colysis as their major energy supply even under normoxic conditions
such as during cell culture. Although glycolysis is less efficient in
generating ATP than oxidative phosphorylation (tricarboxylic acid
cycle), it is much faster and provides substrates to the synthesis of
amino acids, nucleotides, and fatty acids as well as reduces equivalents
to minimize toxic effects of reactive oxygen species [1,2]. The shift in
ATP generation from oxidative phosphorylation to glycolysis even
under normal oxygen conditions is called the Warburg effect. It seems
that the first regulatory step in glycolysis, that is, the increased glucose
uptake, is the biologic basis for the diagnostic procedure of [18F]
fluoro-2-deoxyglucose positron emission tomography (FDG PET)
[3,4]. Although various mechanisms have been proposed to explain
increased FDG uptake in growing tumors, a facilitative glucose trans-
port by glucose transporters (GLUTs) seems to be the most important
[5–7]. GLUT family includes 14 isoforms sharing common structural
features including 12 transmembrane domains with both amino- and
carboxy-terminal ends localized in the cytoplasm [8]. GLUT1 is fre-
quently upregulated in tumor cells, which probably facilitates tumor
growth beyond the size limited by their glycolytic capacity [9]. A
number of studies indicate that increased GLUT1 expression cor-
relates with higher tumor 18F-FDG uptake [10–12].
We have previously demonstrated that statins, which are the 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, can induce
conformational changes in CD20 molecules. This results in impaired
binding of anti-CD20monoclonal antibodies and diminished ability to
trigger complement-dependent cytotoxicity [13]. These effects turned
out to be strictly cholesterol dependent because exogenous cholesterol
could rapidly reverse the effects of statins. Atomic force microscopy,
limited proteolysis, and functional data indicated that statins induced
cholesterol-dependent conformational changes in CD20 tetraspanin.
We hypothesized that statins could also induce conformational changes
in other proteins with multiple membrane-spanning domains. Such
possibility is also supported by a number of observations indicating
that statins or membrane cholesterol depletion impairs the function
of other proteins with multiple membrane-spanning domains including
P-glycoprotein [14], P2X1-4 ATP receptors [15], voltage-gated chloride
channel [16], G-protein–coupled cholecystokinin [17], or serotonin
receptors [18]. Modeling of the serotonin1A receptor revealed that, in
the presence of cholesterol, the receptor acquires a more compact
structure, and its ligands exhibit higher binding energies when docked
to the receptor in the presence of cholesterol [19]. A recent study that
used small-angle neutron scattering revealed that cholesterol-rich micel-
lar nanostructures determine transmembrane protein (GPCR) activity
and that successful reconstitution of the receptor is dependent on
cholesterol-protein interactions [20]. Moreover, cholesterol-binding
motifs have recently been characterized in acetylcholine receptors, which
contain five transmembrane domains [21]. Therefore, we decided to
investigate the influence of statins on the glucose transport into tumor
cells, which frequently overexpress GLUT proteins and require efficient
glucose uptake for their increased metabolic demands.
Materials and Methods
Cell Culture
Human Burkitt lymphoma (Daudi, Raji, Ramos), human follicu-
lar lymphoma (DoHH2), human colon adenocarcinoma (LoVo),
and human embryonic kidney (HEK293T) cell lines were purchased
from the American Tissue Culture Collection (Manassas, VA). Cells
(Daudi, Raji, Ramos, DoHH2, and HEK293T) were cultured in
RPMI 1640 or Dulbecco modified Eagle medium/F-12 medium
(LoVo) supplemented with 10% heat-inactivated fetal bovine serum,
100 μg/ml streptomycin, and 250 ng/ml amphotericin B (all from
Invitrogen, Carlsbad, CA). Cells were cultured at 37°C in a fully
humidified atmosphere of 5% CO2 and were passaged approximately
every other day.
Reagents
The following statins were used: atorvastatin (Pfizer Pharmaceuti-
cals, Inc, Groton, CT), cerivastatin (Bayer Corp, West Haven, CT),
fluvastatin (Novartis Pharma AG, Basel, Switzerland), lovastatin, and
simvastatin (both from Merck, Sharp & Dohme Res. Lab., Rahway,
NJ). Lovastatin and simvastatin were obtained in the inactive lactone
form. They were converted to the active form by dissolving in etha-
nol, heating for 2 hours at 50°C in 0.1N NaOH and neutralizing
with HCl. Distilled water was added to obtain the final stock con-
centration of 10 mM. Stock solution was aliquoted and stored frozen
(−20°C). Mevalonic acid (MA), farnesyl pyrophosphate (FPP), methyl-
β-cyclodextrin (MβCD), and water-soluble cholesterol were purchased
from Sigma (St Louis, MO). Farnesyltransferase inhibitor L-744,832
was obtained from Merck KGaA (Darmstadt, Germany); 6-(N -
(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-6-deoxyglucose (6-NBDG)
was from Invitrogen and was dissolved in dimethyl sulfoxide to
312 Statins Impair Glucose Uptake Malenda et al. Neoplasia Vol. 14, No. 4, 2012
10-mM stock concentration; 4,6-ethylidine-D-glucose (ETDG) was
purchased from Sigma.
Flow Cytometry
For flow cytometry studies, 5 × 105 cells were resuspended in 300 μl
of phosphate-buffered saline (PBS) and incubated with 300 μM
6-[N -(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino]-6-deoxyglucose
(6-NBDG) or with anti-hemagglutinin (HA) phycoerythrin (PE)–
conjugated monoclonal antibody (Miltenyi Biotec, Bergischgladbach,
Germany; 1:10 dilution) or PE-conjugated immunoglobulin G1
(Beckman Coulter, Miami, FL; 1:10 dilution), which served as an iso-
typic control, for 30 minutes at room temperature in dark. As a control
of glucose uptake, 200 mMETDGwas used. Before analysis, cells were
washed twice with PBS and resuspended in 300 μl PBS. Additional
staining with 2.5 μg/ml propidium iodide (Sigma-Aldrich) was
performed to distinguish dead cells. The cells were analyzed on FACS
Scan flow cytometer (Becton Dickinson, Franklin Lakes, NJ) using
CellQuest Pro Software Version 5.2. 6-NBDG uptake was identified
by gating the viable (propidium iodide [PI]–negative) cells. The mean
fluorescence intensity (MFI) served as a measure for 6-NBDG uptake
on a per-cell basis.
Radioisotope Measurement of Glucose Uptake
For the evaluation of [1,2-3H]-deoxy-D-glucose (2-DOG; Perkin-
Elmer, Waltham, MA) uptake, the protocol of Kaliman et al. [22]
was used with minor modifications. Briefly, 3 × 105 cells resus-
pended in 300 μl of transport solution (20 mM HEPES, 150 mM
NaCl, 5 mM KCl, 5 mM MgSO4, 1.2 mM KH2PO4, 25 mM
CaCl2, 2 mM pyruvate, pH 7.4) were incubated for indicated time
with 1.5 μl of 2-DOG (8.0 mCi/ml radionuclide concentration).
2-DOG uptake was stopped by adding 50 mM D-glucose solution
in PBS at 4°C. After a three-time wash in PBS, the cells were lysed
with 0.1 M NaOH + 0.1% SDS solution and left overnight at 4°C
to enable proper cell lysis. To evaluate the nonspecific uptake of
isotope-labeled deoxy-D-glucose (time t0), a stop solution (50 mM
of D-glucose in PBS) was added to the cellular suspension instead
of the PBS solution. The following day, the lysates were analyzed
in a scintillation counter (Wallac, Gaithersburg, MD). All experi-
mental groups were performed in duplicates. The values presented
net uptake per 3 × 105 cells of label, which is the total label accumu-
lated at given time minus the radioactivity bound to the surface of
the cells (time t0).
Cell Cycle Analysis
For the cell cycle analysis, 5 × 105 cells were fixed for 1 hour in
ice-cold 70% ethanol, washed twice with PBS, digested for 10 minutes
with 100 μg/ml RNAse A (Qiagen, Chatsworth, CA) and stained with
5 μg/ml propidium iodide (Sigma). Next, the cells were analyzed with
FACS Scan flow cytometer using CellQuest Pro Software Version 5.2.
G1, S, and G2/M phases of the cell cycle were distinguished according
to the cellular DNA content (≤2n; (2n-4n), ≥4n, respectively).
Lactate Concentration Measurements
Lactate concentration in cell culture supernatants was estimated
electrochemically using lactate oxidase method on ABL Radiometer
ABL 800 FLEX blood gas analyzer (Radiometer Medical ApS,
Brønshøj, Denmark). Values obtained were normalized for total
cellular protein concentration.
Western Blot Analysis
Control or drug-treated cells were washed twice with PBS, pel-
leted, and lysed with 25 mM HEPES, 0.3 M NaCl, 1.5 mM MgCl2,
20 mM β-glycerol-phosphate, 2 mM EDTA, 2 mM EGTA, 1 mM
dithiothreitol, 1% Triton X-100, and 10% glycerol-containing buffer
supplemented with Complete protease inhibitor cocktail (Roche
Diagnostics, Basel, Switzerland). Protein concentration was measured
using Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). Equal amounts
of whole-cell proteins were separated on 10% SDS–polyacrylamide
gel, transferred onto Protran nitrocellulose membranes (Schleicher &
Schuell BioScience, Keene, NH), blocked with Tris-buffered saline
(pH 7.4) and 0.05% Tween 20 supplemented with 5% bovine serum
albumin. Anti-GLUT1 (Millipore, Temecula, CA) rabbit polyclonal
antibody at 1:1000 dilution was used for overnight incubation. After
extensive washing with Tris-buffered saline (pH 7.4) and 0.05%
Tween 20, the membranes were incubated for 45 minutes with anti-
rabbit HRP-coupled secondary antibodies (Jackson Immuno Research,
West Grove, PA). The chemiluminescence reaction for horseradish
peroxidase (HRP) was developed using self-made chemiluminescence
reagent (100 mM Tris pH 8.0, 1.25 mM luminol, 0.2 mM coumaric
acid, 0.006% hydrogen peroxide) and visualized with Stella 8300 bio-
imager (Raytest, Straubenhardt, Germany). The blots were stripped in
0.1 M glycine (pH 2.6) and reprobed with anti-actin-HRP conjugated
rabbit polyconal antibody (Sigma) at 1:50,000 dilution for 45 minutes.
Densitometric analysis was performed using ImageQuant 5.2 software
(Amersham Bioscience, Piscataway, NJ).
Real-time Polymerase Chain Reaction
A total of 1 × 106 cells were washed twice with PBS, pelleted, and
treated with 1 ml of TRIzol reagent (Invitrogen) to extract total RNA
according to the manufacturer’s protocol. RNA concentration was
measured with Bio-Rad spectrophotometer. The first-strand comple-
mentary DNA synthesis containing 100 ng of total RNA was primed
with oligo(dT) using Native AMV Reverse Transcriptase (EurX,
Gdansk, Poland). The primers for GLUT1, GLUT2, GLUT3,
GLUT4, and β2-microglobulin (B2M, reference gene) were custom
designed (Table 1). Quantitative real-time polymerase chain reaction
(RT-PCR) amplification reactions were performed in the LightCycler
II 480 Real-time PCR System (Roche, Mannheim, Germany), using
Table 1. Primers Used for Quantitative RT-PCR.
GLUT1 – (SLC2A1) – NM_006516 CTTTGTGGCCTTCTTTGAAGT CCACACAGTTGCTCCACAT
GLUT2 – (SLC2A2) – NM_000340.1 AGCTGCATTCAGCAATTGGACC ATGTGAACAGGGTAAAGGCCAGG
GLUT3 – (SLC2A3) – NM_006931.2 GACAGCCCATCATCATTTCC TTGAACACCTGCATCCTTGA
GLUT4 – (SLC2A4) – NM_001042.2 CTTCCAACAGATAGGCTCCG CCCCAATGTTGTACCCAAAC
β2-Microglobulin TAGGAGGGCTGGCAACTTAG CCAAGATGTTGATGTTGGATA
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the LightCycler FastStart DNA Master SYBR Green I Kit (Roche).
Data were analyzed using the LightCycler 480 Software 1.5 (Roche).
The fold change for each gene relative to the reference gene (B2M) was
calculated using user-noninfluent, second-derivative method. The spec-
ificity of all the reactions was confirmed through analysis of the PCR
product’s melting profile, obtained by dissociation of the DNA pres-
ent after the amplification step. The primers and reaction parameters
were validated and optimized according to the MIQE (minimum in-
formation for publication of quantitative real-time PCR experiments)
guidelines. In addition, reaction specificity was also confirmed by
agarose gel electrophoresis in which the PCR products were of ex-
pected size.
Generation of Raji and HEK293T Cells Stably
Expressing HA-GLUT1
A pCIS2 vector expressing human GLUT1 gene with an HA tag
built into the first extracellular loop (hereafter called HA-GLUT1)
was a generous gift from Dr Samuel W. Cushman from the National
Institutes of Health, Baltimore, MD. The HA-GLUT1 gene was
cloned into the pLVX-IRES-Puro vector (Clontech Laboratories,
Inc, Mountain View, CA) enabling its lentiviral expression. Next,
HEK293T cells were cotransfected with pLVX-HA-GLUT1-IRES-
Puro, envelope (pMD2.G), and packaging (pPAX2) vectors using
GeneJuice reagent (Calbiochem, San Diego, CA) as a DNA carrier.
pMD2.G and pPAX2 plasmids were obtained from Prof Didier Trono
(École polytechnique fédérale de Lausanne, Switzerland). Lentivirus-
containing supernatants were collected 72 hours after transfection
and added to the culture of Raji or HEK293T cells. Positive clones
were selected with puromycin (Sigma) and evaluated with flow cytom-
etry using anti–HA-PE antibodies as described previously.
Total Cellular Cholesterol Measurements
Cholesterol concentration was quantified in the Amplex Red cho-
lesterol assay (Invitrogen) in whole-cell Raji lysates. Briefly, samples
containing 2.5 × 105 cells were diluted in reaction buffer composed
of 300 μM Amplex Red, 2 U/ml cholesterol oxidase, 2 U/ml choles-
terol esterase, and 2 U/ml HRP. The samples were incubated at 37°C
for 30 minutes in the dark, and fluorescence was measured at Agilent
Bioanalyzer (Agilent Technologies, Santa Clara, CA) equipped with
560-nm excitation and 590-nm emission filters. Cholesterol values
were calculated according to the cholesterol standard curve and
normalized to the protein content as measured with Bio-Rad Protein
Assay (Bio-Rad).
G-actin to F-actin Evaluation
Determination of depolymerized (free globular—G) to polymerized
(filamentous—F) actin was performed using a G-actin/F-actin in vivo
assay kit (Cytoskeleton, Denver, CO) according to the manufacturer’s
protocol. Briefly, 5 × 105 cells were lysed in F-actin stabilization buffer
supplemented with Complete protease inhibitor cocktail (Roche Diag-
nostics). Next, G-fraction was separated from F-fraction with ultra-
centrifugation (100,000g for 1 hour at 37°C; Beckman Coulter).
Supernatants (G-actin) and pellets (F-actin) were separated electropho-
retically in 10% SDS-PAGE gel, blotted onto nitrocellulose membrane
(Schleicher & Schuell BioScience), blocked with Tris-buffered saline
(pH 7.4) and 0.05% Tween 20, and supplemented with 5% nonfat
milk. For β-actin detection, HRP-coupled rabbit polyclonal antibody
(Sigma) was used at 1:100,000 dilution for 1 hour of incubation at
room temperature. The reaction was developed with homemade
chemiluminescence reagent solution (100 mM Tris pH 8.0, 0.2 mM
coumaric acid, 1.25 mM luminol [from Sigma-Aldrich], and 0.006%
H2O2) using Stella bioimager (Raytest).
Membrane Protein Biotinylation
Control- and drug-treated cells (1 × 107 per each experimental
group) washed twice with ice-cold PBS were surface-labeled with
2 mM disulfide-cleavable biotin (EZ-link sulfo-N -hydroxysuccinimido
[NHS]–biotin [Thermo Scientific, Rockford, IL]) dissolved in biotiny-
lation buffer (10 mM triethanolamine, 2 mM CaCl2, 150 mM NaCl,
pH 7.5) for 30 minutes with gentle agitation on ice. The cells were next
washed twice in PBS with 100 mM glycine followed by two washes
with PBS only and lysed in lysis buffer (10% glycerol, 1.0% Triton
X-100, 150 mM NaCl, 5 mM EDTA, 50 mM HEPES, pH 7.4)
enriched with protease inhibitors cocktail Complete protease inhibitor
cocktail (Roche Diagnostics). Next, samples containing equal amounts
of total cellular proteins (300 μg) were incubated overnight at 4°C on a
rotary wheel with 100 μl of immobilized NeutrAvidin agarose resin
(Thermo Scientific)—50% slurry of—to separate the biotinylated
surface proteins from nonbiotinylated intracellular proteins. Next,
neutravidin-coated agarose beads were spun at 400g for 4 minutes,
and the supernatant (nonbiotinylated fraction) was collected and used
subsequently as a control of protein loading. The beads were washed
thrice in a beads wash buffer (20 mMHEPES, pH 7.4, 150 mMNaCl,
10% glycerol, 0.1%Triton X-100) and boiled in Laemmli sample buffer
for 10minutes at 95°Cwith gentle shaking that releases biotinylated pro-
teins from their binding with neutravidin. Membrane (biotinylated) and
cytosolic proteins were subsequently analyzed with Western blot using
anti-GLUT1 (1:1000 dilution; Millipore), anti–intercellular adhesion
molecule 1 (ICAM, 1:1000 dilution, Santa Cruz Biotechnology, Santa
Cruz, CA) or anti-actin HRP-conjugated (1:50,000 dilution; Sigma)
antibodies as described in the Western Blot Analysis section.
Cholesterol Measurements
Total cholesterol concentration in serum of hypercholesterolemic
patients on days 0, 3, and 21 of atorvastatin treatment was estimated
using a standard cholesterol oxidase method with Cobas Integra 800
analyzer (Roche). Approval for the study was obtained from the insti-
tutional review board of the Medical University of Warsaw and was
conducted according to the Declaration of Helsinki. Each patient
signed a written informed consent for the procedures.
Leukocyte Isolation from Blood
Peripheral blood sample (5 ml) of patients was collected before
(day 0), on the third day (day 3), or after 3 weeks (day 21) of ator-
vastatin (20 mg/day) treatment. The blood was diluted twice with
PBS. Next, 3 ml of Histopaque-1077 (Sigma-Aldrich) was pipetted
into conical centrifuge tubes. Ten milliliters of diluted peripheral
blood was slowly layered on the top of Histopaque layer. Next, tubes
were centrifuged (400g for 30 minutes at 21°C) without brake. The
buffy coats were isolated and washed twice with PBS. The leukocyte
pellet was resuspended in 3 ml of PBS and counted in a Brüker
chamber using Türk dye. Peripheral blood leukocytes were used to
determine 2-DOG uptake according to the protocol described in the
Radioisotope measurement of glucose uptake section of the Materials
and Methods. Approval for the study was obtained from the institu-
tional review board of the Medical University of Warsaw and was
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conducted according to the Declaration of Helsinki. Each patient
gave a written informed consent for the procedures.
Positron Emission Tomography/Computed Tomography
Whole-body PET/CT examinations in three-dimensional mode
(2 minutes per bed position) were performed on PET/CT scanner
Biograph 64TruePoint (SiemensMedical Solutions, Erlangen,Germany).
The PET studies were performed 55 to 65 minutes after injection of
350 to 360MBq 18F-FDG. All patients were requested to drink 1.5 L of
water-equivalent oral contrast dispersion. Immediately before the PET/
CT examination, patients were requested to empty their bladder. Patients
were positioned head first supine on the common patient handling
system with the arms raised in according with standard CT practice.
Coaxial whole-body imaging ranges were defined on the Topogram,
covering the area from the skull to the upper thighs (2 minutes, six to
seven PETbed positions depending on the size of the patient—one PET
bed have approximately 15 cm). CTwas performed in spiral mode using
a continuous acquisition at 120 kV, 170 mAs, 2-mm slice width, and
pitch of 0.8. Emission data were reconstructed with attenuation cor-
rection based on low-dose CT. PET emission data were reconstructed
(reconstruction method—TrueX) using an attenuation-weighted
approach on 168 × 168 matrices and with a 4-mmGaussian postrecon-
struction filtering (two iterations, 14 subsets). The PET/CT images
were assessed using Multimodality Work Station Syngo (TrueD) by
Siemens. All pathologic foci of 18F-FDG uptake were included in
the evaluation. Uptake in organs was evaluated assuming a uniform
distribution in the organ of interest. Regions of interest (ROIs)
were drawn around each foci. Maximum standardized uptake values
(SUVmax) were calculated in all ROIs. CT data were used for allocation
of regions with increased uptake of the radiopharmaceutical to specific
morphologic structures. The study was approved by the ethical
Figure 1. Lovastatin decreases glucose uptake in Raji cells in a time- and dose-dependent fashion. (A) Human Burkitt lymphoma Raji
cells were incubated for 48 hours with 10 μM lovastatin. Next, 3 × 105 cells resuspended in 300 μl of transport solution were incubated
for 15, 30, or 60 minutes with 1.5 μl of 2-DOG (8.0 mCi/ml radionuclide concentration), and after a three-time wash in cold PBS, the cells
were lysed and analyzed in a scintillation counter. The figure presents mean counts per minute (cpm) value ± SD. *P < .05 versus
controls in Student’s t test. (B) Raji cells were incubated for 48 hours with 10 μM lovastatin. Next, 3 × 105 cells were stained for 15,
30, or 60 minutes with 300 μM 6-NBDG in PBS, and after a three-time wash in cold PBS, the cells were analyzed with flow cytometry.
The figure presents MFI ± SD after background subtraction (MFI of Raji cells preincubated for 15 minutes with 200 mM 4,6-ETDG that
serves as an extracellular GLUT1 inhibitor). *P< .05 versus controls in Student’s t test. (C) Raji cells were incubated for 48 hours with the
indicated lovastatin concentrations. Next, 3 × 105 cells were incubated for 30 minutes with 2-DOG, and after a three-time wash in cold
PBS, the cells were lysed and analyzed in a scintillation counter. The figure presents mean cpm ± SD. *P < .05 versus controls in
Student’s t test. (D) Raji cells were incubated for 48 hours with the indicated lovastatin concentrations. Next, 3 × 105 cells were stained
for 30 minutes with 300 μM 6-NBDG in PBS, and after a three-time wash in cold PBS, the cells were analyzed by flow cytometry. The
figure presents MFI ± SD after background subtraction. *P < .05 versus controls in Student’s t test. (E) Raji cells were incubated for
indicated time with 10 μM lovastatin. Next, 3 × 105 cells were incubated for 30 minutes with 2-DOG, and after a three-time wash in cold
PBS, the cells were lysed and analyzed in a scintillation counter. The figure presents mean cpm ± SD as a percentage of controls. *P< .05
versus controls in Student’s t test.
Table 2. Changes in Lactate Concentration Correlate with Impaired Glucose Uptake in Raji Cells.
Group Lactate Concentration in
Medium (Mean μmol of





% of PI-Positive Cells
(Mean ± SD)
Controls 0.215 ± 0.005 79.21 ± 4.75 10.03 ± 0.28
10 μM lovastatin
for 24 h
0.116 ± 0.005* 63.90 ± 0.07* 14.10 ± 6.5
10 μM lovastatin
for 48 h
0.091 ± 0.002* 30.75 ± 2.40* 14.85 ± 0.54
*P < .05 versus controls (Student’s t test).
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committee of Medical University of Warsaw. All patients have given an
informed consent.
Results
Lovastatin Inhibits Glucose Uptake
To investigate the influence of cholesterol synthesis, inhibitors on
the glucose uptake Raji cells were preincubated with 10 μM lovastatin
for 48 hours and, after washing with PBS, were incubated with
either tritiated 2-DOG or 6-NBDG. Glucose uptake was measured
after 15, 30, or 60 minutes of incubation after extensive washing of
cells with PBS using scintillation counter or flow cytometry. The
results of these experiments revealed that the glucose uptake was
strongly suppressed in lovastatin-pretreated cells compared with con-
trols with a maximum of almost three-fold decrease in uptake
observed for 2-DOG at 15 minutes and for 6-NBDG at 60 minutes
(Figure 1, A and B). Lovastatin-mediated inhibition of glucose
uptake was concentration dependent, observed already at 5 μM
lovastatin concentration for both 2-DOG and 6-NBDG (Figure 1,
C and D). The inhibition of glucose uptake was unlikely to result
from unspecific binding of lovastatin to GLUTs that could lead to
inhibition of their activity because it occurred after at least a 48-hour
incubation (Figure 1E ). Inhibition of glucose uptake correlated with
decreased lactate production in cells incubated with 10 μM lovastatin
for 24 and 48 hours (Table 2). Lovastatin-mediated inhibition of
glucose uptake was also observed in other cell lines including Daudi,
Ramos, DoHH2 lymphomas, LoVo colon adenocarcinoma, as well
as HEK293T cells (Figure 2A). It was previously shown that glucose
uptake can be dependent on the rate of tumor cells’ proliferation
[23,24]. However, at studied concentrations, lovastatin did not
significantly affect the cell cycle of Raji cells. In controls, 51% of cells
were in the G1 phase, 26% were in the S phase, and 23% were in the
G2 phase. In cells incubated with 10 or 20 μM lovastatin, the values
were 60% and 63% for the G1 phase, 19% and 20% for the S phase,
and 21% and 17% for the G2 phase, respectively (Figure 2B). Analysis
of cytostatic/cytotoxic effects measured using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay has also demonstrated that
lovastatin is not toxic at the concentrations studied (data not shown).
Other statins, including cerivastatin, simvastatin, fluvastatin, and ator-
vastatin (all except 1 μM cerivastatin were used at 10 μM concentra-
tions), have also significantly impaired 6-NBDG uptake by Raji cells
(Figure 2C ).
Lovastatin Does Not Impair Expression of GLUT Genes
Statins can modulate expression of many different genes. Quanti-
tative RT-PCR was used to determine the influence of lovastatin on
the expression of GLUT genes, including GLUT1, GLUT2,
Figure 2. Statins decrease glucose uptake in human malignant and nonmalignant cell lines. (A) Human Burkitt lymphoma (Daudi,
Ramos), follicular B-cell lymphoma (DoHH2), colon adenocarcinoma (LoVo), and embryonic kidney (HEK293T) cells were incubated
for 48 hours with 10 μM lovastatin. Next, 3 × 105 cells were stained for 30 minutes with 300 μM 6-NBDG in PBS and after a three-time
wash in cold PBS, the cells were analyzed with flow cytometry. The figure presents MFI ± SD after background subtraction. *P < .05
versus controls in Student’s t test. (B) Raji cells were incubated for 48 hours with 10 or 20 μM lovastatin. Next, 5 × 105 cells were fixed
for 1 hour in ice-cold 70% ethanol, washed, stained with 5 μg/ml of propidium iodide, and analyzed with flow cytometry. The figure
presents the percentage distribution of cells in the G1, S, and G2/M cell cycle phase. (C) Raji cells were incubated for 48 hours with 1 μM
cerivastatin (Cer), 10 μM simvastatin (Sim), 10 μM fluvastatin (Flu), and 10 μM atorvastatin (Ator). Next, 3 × 105 cells were stained for
30 minutes with 300 μM 6-NBDG in PBS, and after a three-time wash in cold PBS, the cells were analyzed with flow cytometry. The
figure presents MFI ± SD after background subtraction. *P < .05 versus controls in Student’s t test.
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GLUT3, and GLUT4 in Raji cells. The expression of investigated
GLUTs did not change in cells incubated with 10 μM lovastatin
(Figure 3A). Also, at the protein level, the amount of GLUT1 did
not change in lovastatin-treated Raji cells compared with controls
(Figure 3B). Determination of other GLUT proteins was not possi-
ble owing to the poor quality of available antibodies.
To address the potential influence of statins on the transcriptional
regulation of glucose transport in more detail, Raji cells were stably
transduced with lentiviral vector encoding HA-tagged GLUT1 under
constitutive CMV promoter. Glucose uptake by HA-GLUT1–
transduced Raji and HEK cells was significantly higher as compared
with controls (Figure 3, C and E ). However, incubation of control and
HA-GLUT1–transduced Raji and HEK cells with 10 μM lovastatin
for 48 hours resulted in significant inhibition of glucose uptake (Fig-
ure 3,D and F ), indicating that it is the activity and not the expression
level of GLUT1 that is suppressed in lovastatin-treated cells.
Figure 3. Lovastatin does not influence overall expression of GLUT 1, 2, 3, and 4 but impairs glucose uptake in HA-GLUT1 overexpres-
sing cells. (A) Raji cells were incubated for indicated time with 10 μM lovastatin. Next, the expression of GLUT1, GLUT2, GLUT3, and
GLUT4 was evaluated in quantitative RT-PCR. The figure presents mean target-to-reference ratio ± SD. (B) Raji cells incubated for 1 hour
to 48 hours with 10 μM lovastatin were lysed, and total GLUT1 protein levels were analyzed with Western blot analysis. Actin served as a
loading control. The figure shows the representative result. The obtained data were semiquantified with densitometry. (C) 6-NBDG
uptake by wild-type (wt) and HA-GLUT1–expressing (HA-GLUT1) Raji cells. A total of 3 × 105 cells were stained for 30 minutes with
300 μM 6-NBDG in PBS, and after a three-time wash in cold PBS, the cells were analyzed with flow cytometry. The figure presents MFI
± SD after background subtraction. *P < .05 versus wt cells in Student’s t test. (D) Nontransduced (wt) and HA-GLUT1–expressing Raji
cells (HA-GLUT1) were incubated for 48 hours with 10 μM lovastatin. Next, 3 × 105 cells were stained for 30minuteswith 300 μM6-NBDG in
PBS, and after a three-time wash in cold PBS, the cells were analyzed with flow cytometry. The figure presents MFI ± SD after background
subtraction. *P< .05 versus control wt group in Student’s t test. **P< .05 versus control HA-GLUT1 group in Student’s t test. “C” stands for
control (=no lovastatin-treated) group of each cell line, “L” stands for lovastatin-treated group. (E) 6-NBDG uptake by wild-type (wt) and HA-
GLUT1–expressing (HA-GLUT1) HEK293T cells. A total of 3 × 105 cells were stained for 30 minutes with 300 μM6-NBDG in PBS, and after a
three-timewash in cold PBS, the cells were analyzed with flow cytometry. The figure presentsMFI ± SD after background subtraction. *P<
.05 versus wt cells in Student’s t test. (F) Nontransduced (wt) and HA-GLUT1–expressing HEK293T cells (HA-GLUT1) were incubated for
48 hours with 5 μM lovastatin. Next, 3 × 105 cells were stained for 30 minutes with 300 μM 6-NBDG in PBS, and after a three-time wash
in cold PBS, the cells were analyzed with flow cytometry. The figure presents MFI ± SD after background subtraction. *P < .05 versus
control wt group in Student’s t test. **P < .05 versus control HA-GLUT1 group in Student’s t test. “C” stands for control (=no lovastatin-
treated) group of each cell line; “L” stands for lovastatin-treated group.
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GLUT4 undergoes cycling from the plasma membrane through
an actin-dependent fast endocytosis and slow exocytosis that can
be accelerated by insulin [25]. In contrast, GLUT1 is an insulin-
independent, constitutive transporter, and there is no strong evidence
indicating its cycling between membrane and endosomal compart-
ments. To investigate the possibility that statins might interfere with
GLUT cycling, the influence of statins on the organization of actin
fibers was investigated. Phalloidin and cytochalasin D were used as
positive controls to either promote or disrupt actin polymerization,
respectively (Figure 4A). However, neither lovastatin nor atorvastatin
was able to influence the organization of actin fibers in Raji cells
(Figure 4B). Additional experiments with biotinylation of extra-
cellular proteins followed by immunoprecipitation revealed that the
levels of GLUT1 in intracellular as well as membrane compartments
remain comparable in control and lovastatin-treated cells (Figure 4C ).
These results indicate that lovastatin does not affect trafficking of
GLUT1 proteins in Raji cells.
Impaired Glucose Uptake Results from Inhibition of
Cholesterol Synthesis
Incubation of Raji cells with lovastatin decreased total cholesterol
content by 15% (Table 3). Considering that cholesterol concentra-
tion is tightly regulated in mammalian cells, this 15% drop is highly
relevant. Cholesterol depletion can be achieved using MβCD, which
acutely extracts cholesterol from the exoplasmic leaflet of the plasma
membrane [26]. A 30-minute incubation of Raji cells with 5 mg/ml
of MβCD resulted in almost four-fold inhibition of 6-NBDG
uptake (Figure 5A), indicating the possibility that statin-mediated
impairment of intracellular glucose transport might result from
diminished plasma membrane cholesterol content. Statin-mediated
inhibition of cholesterol synthesis can be restored by exogenous MA
or FPP [27]. Coincubation of Raji cells with 10 μM lovastatin and
10 μM FPP or 200 μMMA resulted in restoration of glucose uptake
in Raji cells (Figure 5B). Moreover, L-744,832, a farnesyltransferase
inhibitor, increased rather than decreased glucose uptake by Raji
cells, indicating that impaired statin-mediated glucose transport is
unlikely to be caused by interference with protein prenylation
(Figure 5C ). Repletion of cellular cholesterol with cholesterol-MβCD
complexes restored glucose uptake in lovastatin-treated cells (Figure 5,
D and E ).
Influence of Atorvastatin on Glucose Uptake by Peripheral Blood
Mononuclear Cell in Patients
A small exploratory clinical study was performed to investigate the
influence of cholesterol depletion in freshly isolated peripheral blood
mononuclear cells (PBMCs) from patients diagnosed with hyper-
cholesterolemia who were treated with atorvastatin. Eight patients
were treated for 3 weeks with a daily dose of 20 mg atorvastatin to
reduce their cholesterol blood concentration and to determine the
glucose uptake in freshly isolated PBMCs. Peripheral blood was col-
lected on days 0 (before administration of atorvastatin), 3, and 21 to
measure plasma cholesterol concentration and 2-DOG uptake. In
three patients (patients 1, 2, and 4 in Figure 6), there was a cor-
relation between decreased plasma cholesterol concentration and
2-DOG uptake, although in patient 4, there was an initial drop in
cholesterol concentration accompanied by a decrease in 2-DOG
uptake, followed by a rise in both parameters on day 21. In the remain-
ing patients, despite a slightly decreased cholesterol concentration
on day 3, there was an increase in 2-DOG uptake, but after 3 weeks,
a decreased cholesterol concentration was accompanied by a drop in
2-DOG uptake. A higher variability of results obtained in a hetero-
geneous population of patients compared with cell culture models,
where all experimental conditions are well controlled, might result
from several factors. For example, differences in nutritional habits,
stress level, sport activity, and others might all affect the final results
obtained in the pilot study. Also, genetic polymorphisms in various
metabolic pathways can be expected to play a role. At least to some
extent, the variability might also result from the patients’ incomplete
adherence to the prescribed atorvastatin.
Figure 4. Statins do not influence actin fibers’ organization as well
as membrane GLUT1 protein expression in Raji cells. (A) Control
experiment—Raji cell lysates were incubated for 5 minutes with
1 μM phalloidin (Phall) or 10 μM cytochalasin D (Cyt). After ultra-
centrifugation, F (fibrillar) and G (globular) fractions were eval-
uated in Western blot analysis. (B) Raji cells were incubated for
24 or 48 hours with 10 μM lovastatin (L) or atorvastatin (A). Next,
F (fibrillar) and G (globular) fractions in cell lysates were evaluated
in Western blot analysis using G-actin/F-actin in vivo assay kit
from Cytoskeleton. (C) Membrane proteins of Raji cells incubated
for 1 hour to 48 hours with 10 μM lovastatin were labeled with
cell-nonpermeable NHS biotin. Next, the cells were lysed, and
biotin-bound membrane proteins were precipitated with neutravidin
beads. The figure presents Western blot results of membrane and
cytosolic protein fractions for GLUT1, ICAM1 (membrane protein
control), and actin (cytosolic protein control). cyt (cytosolic fraction)
and m (membrane fraction) served as controls for subsequent anti-
body reactivity. nb indicates nonbiotinylated group.
Table 3. Changes in Cellular Cholesterol Concentration on Incubation with Lovastatin.
Group Amount of Cholesterol in 2.5 × 105 Cells
(Mean ± SD; ng)
Controls 2.89 ± 0.02
10 μM lovastatin for 48 h 2.46 ± 0.09*
10 μM lovastatin + 200 μM MA for 48 h 2.71 ± 0.04†
*P < .05 versus controls (Student’s t test).
†P < .05 versus lovastatin-treated group (Student’s t test).
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Influence of Atorvastatin on 18F-FDG Uptake in Cancer Patients
The influence of statins on glucose uptake might affect the diagnostic
procedures using 18F-FDG PET. To investigate this possibility, PET/
CT with 18F-FDG examinations were performed before and after
atorvastatin treatment in four patients (briefly described in Table 4)
referred to the Nuclear Medicine Department of Medical University
of Warsaw. Second PET/CT imaging was performed within a 1-week
period after administration three atorvastatin doses of 40 mg. The
imaging parameters (dose and time of acquisition) and protocol on
patient preparation were comparable in both examinations. 18F-FDG
uptake was not suppressed in patients 2, 3, and 4. However, a strongly
decreased 18F-FDGuptake was observed in patient 1. In this patient, base-
line SUVmax levels were 12.8 (range = 12.3-16.7) and 5.95 (range = 5.6-
8.9) before and after atorvastatin treatment, respectively (Table 5). A
PET/CT scan of thoracic cavity before and after atorvastatin treatment,
indicating decreased 18F-FDG uptake in patient 1, is shown in Figure 7.
Discussion
Statins are among the most frequently prescribed drugs. They exert lipid-
lowering effects and are used in the prevention and treatment of cardio-
vascular diseases. Besides lowering plasma cholesterol concentration,
statins exert pleiotropic effects that are presumed to be independent of
their cholesterol-lowering properties [28,29]. These include improved
endothelial function, decreased vascular inflammation, neuroprotection,
and many others [29]. Intriguingly, some of these putative pleiotropic
effects might be detrimental and responsible for the adverse effects of
statin treatment. For example, potential diabetogenic effects of statins
have been reported in a randomized trial of rosuvastatin for primary pre-
vention (JUPITER) [30]. Although these observations are at odds with
previous primary prevention statin trial (WOSCOPS) [31], a recent
collaborative meta-analysis that collected data from 13 large placebo-
controlled trials indicate that statin therapy is associated with a slightly
increased risk of development of diabetes [32,33]. Also, a lipid-modifying
niacin has been reported to increase the risk of developing diabetes [34].
Together with the findings reported here showing statin-mediated modula-
tion of GLUT activity, the clinical observations revealing alterations in
glucose metabolism might be specifically related to drug-induced influence
on cholesterol levels. This possibility can be strengthened by our preliminary
studies, also indicating that statins impair glucose uptake in a number of
normal cells of hepatic, adipose, muscle, or endothelial origin (not shown).
Figure 5. Effects of lovastatin on glucose uptake depend on the cholesterol biosynthesis pathway. (A) Raji cells were incubated for 30 min-
utes with 5 mg/ml MβCD. Next, 3 × 105 cells were stained for 30 minutes with 300 μM 6-NBDG in PBS, and after a three-time wash in cold
PBS, the cells were analyzed with flow cytometry. The figure presents MFI ± SD after background subtraction. *P < .05 versus controls in
Student’s t test. (B) Raji cells were incubated for 48 hours with 10 μM lovastatin (L), 10 μMFPP (F), and/or 200 μMMA (M). Next, 3 × 105 cells
were stained for 30 minutes with 300 μM 6-NBDG in PBS, and after a three-time wash in cold PBS, the cells were analyzed with flow cyto-
metry. The figure presents MFI ± SD after background subtraction. *P< .05 versus controls in Student’s t test. **P< .05 versus lovastatin-
treated group in Student’s t test. (C) Raji cells were incubated for 48 hours with 10 μM lovastatin (L) and 10 μMor 20 μM farnesyltransferase
inhibitor L-744,832 (FI). Next, 3 × 105 cells were stained for 30minuteswith 300 μM6-NBDG in PBS, and after a three-timewash in cold PBS,
the cells were analyzed with flow cytometry. The figure presents MFI ± SD after background subtraction as a percentage of controls. *P<
.05 versus controls in Student’s t test. (D) Raji cells were incubated for 48 hours with 10 μM lovastatin (L). For the last 30 minutes of
incubation, 0.2 mg/ml of water-soluble cholesterol-MβCD (chol) was added. Next, 3 × 105 cells were stained for 30 minutes with 300 μM
6-NBDG in PBS, and after a three-time wash in cold PBS, the cells were analyzed with flow cytometry. The figure presents MFI ± SD after
background subtraction. *P < .05 versus lovastatin-treated group in Student’s t test. (E) Raji cells were incubated for 48 hours with 10 μM
lovastatin (L). For the last 30minutes of incubation, 0.2mg/ml of water-soluble cholesterol-MβCD (chol) was added. Next, 3 × 105 cells were
incubated for 30minuteswith 2-DOG, and after a three-timewash in cold PBS, the cells were lysed and analyzed in a scintillation counter. The
figure presents mean cpm ± SD. *P < .05 versus lovastatin-treated group in Student’s t test.
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Because HMG-CoA reductase is the rate-limiting enzyme of the
mevalonate pathway, potential mechanisms underlying some of these
pleiotropic effects include the inhibition of isoprenoid synthesis by
statins. Prenyl groups serve as lipid attachments for posttranslational
modifications of proteins such as lamins, Ras, Rho, Rap, Rac, and
Cdc42 [35]. Isoprenylated proteins constitute up to 2% of all cellular
proteins, and their isoprenylation is necessary for correct subcellular
localization and function. Other cholesterol-independent effects of
statins have also been reported. For example, statins can bind to β2-
integrin leukocyte function-associated antigen 1, thereby impairing its
function, independently of their influence on the mevalonate pathway
[36]. Statins can also affect glycosylation of cellular proteins by inhib-
iting the mevalonate pathway–derived dolichols and might negatively
affect muscle function owing to the inhibition of ubiquinone (coen-
zyme Q10) production [37,38]. Accumulating evidence indicates that
statins can also exert certain effects independently of lowered plasma
cholesterol levels, but still resulting from diminished cholesterol syn-
thesis in cells. For example, statins might affect composition and
structure of lipid rafts thereby modulating multiple signaling path-
ways [39,40]. Moreover, we have previously shown that statins can
induce conformational changes within CD20 tetraspanin that were
reversed by the addition of exogenous cholesterol [13]. Membrane
cholesterol levels are strictly controlled and multiple complex mech-
anisms are evolved, which maintain its homeostasis within a narrow
range [41]. Cholesterol is thought to rigidify the fluid plasma mem-
brane to reduce passive permeability and increase its mechanical prop-
erties [42]. However, the role of this lipid seems to be more complex.
Cholesterol can associate with a number of membrane proteins, either
covalently or through noncovalent interactions. Moreover, cholesterol
allows condensation of membrane lipids, thus decreasing the area per
molecule [43]. Because plasma membrane behaves as an incompress-
ible fluid, the addition of cholesterol increases its total thickness and
allows its reorganization. This has significant consequences for the
functioning of membrane-embedded proteins [43].
GLUT1 is among the most intensively studied transmembrane
proteins; despite this, little is known about the mechanism of glucose
transport [44]. It seems that glucose transport occurs through sub-
strate binding–induced conformational change in GLUT1 that leads
to substrate translocation [45]. GLUT proteins are extremely diffi-
cult to crystallize [44]. Moreover, obtaining crystal structures of
membrane-embedded proteins poses additional technical difficulties
[46] and only a few proteins have been crystallized in lipid environ-
ment [47,48]. Therefore, direct investigation of conformational
changes in GLUTs induced by statins will require significant tech-
nical advancements.
Figure 6. Statins impair glucose uptake in PBMCs. PBMCs were
isolated from blood samples collected from patients at days 0, 3,
and 21 of atorvastatin treatment (20 mg/d orally). Next, the 2-DOG
uptake was evaluated as described in the corresponding Materials
and Methods section. The figure presents results of plasma cho-
lesterol levels (right vertical axis) and 2-DOG uptake (left vertical
axis) in eight independent patients.
Table 4. Clinical Data of Four Patients Examined with 18F-FDG PET/CT Imaging Included into
the Study.
Patient Age (years) Sex Disease
1 68 M Mantle cell lymphoma
2 45 F Follicular lymphoma
3 48 F Neuroendocrine tumors with unknown primary site
4 18 F Hodgkin disease
Table 5. 18F-FDG PET/CT Results Obtained in Four Patients before and 3 Days after Initiation
of Atorvastatin Treatment.




1 Cervical lymph node 16.7 8.9
Supraclavicular lymph node 12.7 5.9
Paratracheal lymph node 14.4 7.1
Supracarina lymph node 15.2 6.2
Axillary lymph node 12.3 5.7
Para-aortic lymph node 12.6 5.6
Iliac lymph node 12.9 5.8
Inguinal lymph node 12.7 6
2 Cervical lymph node 6.7 7.6
Supramandibular lymph node 8.9 10.4
Lateral neck lymph node 4.5 4.8
Para-aortic lymph node 4.1 4.6







4 Anterior mediastinum mass 8.4 7.3
Mediastinum lymph node 5.3 5.3
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Figure 7. 18F-FDG PET/CT examination in the patient with mantle cell lymphoma—thoracic scan. (A) Before atorvastatin treatment.
(B) Examination of the same anatomic region repeated after three doses of atorvastatin treatment shows a significant decrease in
18F-FDG uptake in lymph nodes.
Figure 8. Localization of putative cholesterol-binding motifs in the homology model of human GLUT1 protein. (A) Sequences of
cholesterol-binding motifs. (B) A homology model of human GLUT1 protein: N- and C-termini are indicated and the placement within
the plasma membrane is only schematic. Disordered/unstructured regions (residues 225-260 and 470-490) are indicated by dashed
lines. (C) Putative CRAC-like motifs in GLUT1: aa 83-89 (VGLFVNR, left) and aa 322-330 (VSLFVVER, right).
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Proteins that interact with cholesterol contain an amino acid
consensus sequences termed cholesterol recognition/interaction amino
acid consensus (CRAC) or CRAC-like within their juxtamembrane
regions [49]. A recent study revealed that acetylcholine receptors
contain an inverted CRAC, or CARC motifs within the mem-
brane-embedded regions of the receptor [21]. To identify putative
CRAC, CRAC-like, or CARC motifs within GLUT, a bioinformatics
analysis was performed. The structure of the human GLUT1 protein
was predicted by the comparative modeling approach. First, the Gene-
Silico metaserver [50] was used to identify the best template for mod-
eling of GLUT1. It identified the structure of the glycerol-3-phosphate
transporter from Escherichia coli as the most closely related protein to
GLUT1 with experimentally determined structure (Protein Data Bank
code 1pw4) and provided a series of sequence alignments. Homology
modeling was carried out using the “FRankenstein’s monster” approach,
in which a protein structure is constructed by iterative model building
and splicing fragments from alternative models (see Kosinski et al. [51]
for a detailed description of the protocol). This analysis revealed the pres-
ence of two CRAC-like cholesterol interaction consensus sequences
within a membrane-embedded region of GLUT1 (Figure 8).
Our studies reveal that statins do not inhibit expression of GLUT
proteins, and their influence on glucose transport can be reversed by
addition of exogenous metabolites of cholesterol biosynthesis path-
way (MA or FPP). Moreover, statin-induced effects can be swiftly,
that is, within 30 minutes, reversed by coculture of tumor cells with
cholesterol-MβCD complexes that restore plasma membrane choles-
terol content. Also, MβCD, which extracts cholesterol from plasma
membrane is able to induce rapid changes in glucose uptake that
would outpace potential influence on the transcriptional regulation
of genes encoding GLUTs. These observations indicate that statins
are unlikely to impair glucose uptake at transcriptional level. Although
statins can also influence posttranscriptional prenylation of multiple
proteins, including Rab proteins that regulate endocytosis and exo-
cytosis as well as intracellular trafficking of multiple proteins, there
are no data indicating that GLUT1 could be regulated in this manner.
Moreover, neither lovastatin nor atorvastatin, at least at the concen-
trations used, was able to affect the polymerization of actin fibers that
might influence the trafficking of GLUT proteins.
Altogether, the results of this study indicate that statins can effec-
tively inhibit glucose uptake by tumor cells. The relevance of this
observation might be double-edged. On one hand, statins might
interfere with tumor cells’ metabolism, thereby impairing adaptation
of tumor cells to microenvironmental conditions associated with
tumor progression. It is possible that the reported statin-dependent
induction of autophagy in tumor cells [52] results from impaired glu-
cose uptake that triggers autophagy to gain a different source of
energy in rapidly proliferating cells. On the other hand, the influence
of statins on glucose uptake might be detrimental in diagnostic pro-
cedures using 18F-FDG PET. Our observation should inspire further
studies to see if a temporary withdrawal from statin treatment can
increase the sensitivity of this diagnostic procedure.
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